AR125991A2 - Preparación farmacéutica - Google Patents

Preparación farmacéutica

Info

Publication number
AR125991A2
AR125991A2 ARP220101408A ARP220101408A AR125991A2 AR 125991 A2 AR125991 A2 AR 125991A2 AR P220101408 A ARP220101408 A AR P220101408A AR P220101408 A ARP220101408 A AR P220101408A AR 125991 A2 AR125991 A2 AR 125991A2
Authority
AR
Argentina
Prior art keywords
hcg
sialylation
pharmaceutical preparation
mol
optionally
Prior art date
Application number
ARP220101408A
Other languages
English (en)
Inventor
Ian Plaskin Daniel White Richard Boyd Cottingham
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR125991A2 publication Critical patent/AR125991A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Preparaciones que incluyen hCG recombinante (r hCG). Reivindicación 1: hCG recombinante (r hCG) incluyendo la sialilación de a2,3- y a2,6. Reivindicación 16: hCG recombinante en conformidad con la reivindicación 13 o una preparación en conformidad con la reivindicación 14 o una composición farmacéutica en conformidad con la reivindicación 15 que incluya un contenido de ácido siálico [expresado en términos de relación de moles de ácido siálico con moles de proteína] de 15 mol/mol o mayor, opcionalmente en la cual 10% o más de la sialilación total sea a2,3- y/o opcionalmente en la cual 50% o menos de la sialilación total sea sialilación a2,6-.
ARP220101408A 2009-10-05 2022-05-27 Preparación farmacéutica AR125991A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05

Publications (1)

Publication Number Publication Date
AR125991A2 true AR125991A2 (es) 2023-08-30

Family

ID=41471027

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100103608A AR079876A1 (es) 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma
ARP220101408A AR125991A2 (es) 2009-10-05 2022-05-27 Preparación farmacéutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100103608A AR079876A1 (es) 2009-10-05 2010-10-05 Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma

Country Status (25)

Country Link
US (5) US8975226B2 (es)
EP (2) EP2486051B1 (es)
JP (6) JP6176924B2 (es)
KR (7) KR102213154B1 (es)
CN (1) CN107050434B (es)
AR (2) AR079876A1 (es)
AU (1) AU2010304922B2 (es)
BR (1) BR112012007990A2 (es)
CA (1) CA2776790A1 (es)
DK (1) DK2486051T3 (es)
ES (1) ES2798258T3 (es)
HR (1) HRP20200941T1 (es)
HU (1) HUE050793T2 (es)
IL (3) IL218548A (es)
IN (1) IN2012DN02073A (es)
JO (1) JOP20200039A1 (es)
LT (1) LT2486051T (es)
MX (1) MX2012003951A (es)
PL (1) PL2486051T3 (es)
PT (1) PT2486051T (es)
RS (1) RS60413B1 (es)
RU (2) RU2588650C2 (es)
SI (1) SI2486051T1 (es)
TW (2) TWI532495B (es)
WO (1) WO2011042688A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN103619358B (zh) 2011-03-31 2017-02-15 辉凌公司 药物制剂
AR090095A1 (es) * 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
SG10201704774VA (en) 2012-12-10 2017-07-28 Seikagaku Kogyo Co Ltd Novel recombinant factor c and method for producing the same, and method for measuring endotoxin
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
UA124187C2 (uk) 2015-04-24 2021-08-04 Феррінг Б.В. Спосіб отримання гонадотропіну
MX2017016437A (es) 2015-06-26 2018-03-02 Ferring Bv Metodos de purificacion y/o inactivacion viral.
EP3787667A1 (en) 2018-04-30 2021-03-10 Ferring B.V. Composition for controlled ovarian stimulation
US20210244821A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) * 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
BR9510567A (pt) * 1995-03-21 1998-06-23 Applied Research Systems Formulaçoes líquidas de hcg
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
ATE439439T1 (de) 1997-06-25 2009-08-15 Merck Serono Sa Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
CN1352566A (zh) * 1999-05-07 2002-06-05 应用研究系统Ars股份公司 促性腺激素
EA006605B1 (ru) * 2000-02-22 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. СПОСОБ ОЧИСТКИ РЕКОМБИНАНТНОГО чХГ
EA009330B1 (ru) 2001-09-12 2007-12-28 Апплайд Резеч Системз Арс Холдинг Н.В. Способ содействия имплантации и/или снижения частоты выкидышей и набор для его осуществления
WO2004099231A2 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EA007030B1 (ru) * 2001-10-22 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Гонадотропины для фолликулогенеза
AU2002335585B2 (en) * 2001-10-29 2007-08-16 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
AU2004226353A1 (en) * 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005017130A2 (en) * 2003-08-18 2005-02-24 Glycotope Gmbh Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
ATE476666T1 (de) * 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CN103627670B (zh) * 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
EP1861124A2 (en) * 2005-03-11 2007-12-05 Fresenius Kabi Deutschland GmbH Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch
WO2007022206A1 (en) 2005-08-15 2007-02-22 Siemens Vdo Automotive Corporation Automotive diesel exhaust hc dosing valve
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
WO2008057683A2 (en) * 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
TWI488640B (zh) * 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN103619358B (zh) * 2011-03-31 2017-02-15 辉凌公司 药物制剂
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
US8975226B2 (en) 2015-03-10
EP3611185A1 (en) 2020-02-19
SI2486051T1 (sl) 2020-08-31
RU2016118236A (ru) 2018-10-29
US20220340634A1 (en) 2022-10-27
JP2018076296A (ja) 2018-05-17
JP2020000246A (ja) 2020-01-09
US20180030107A1 (en) 2018-02-01
AU2010304922A1 (en) 2012-03-29
JP2016074680A (ja) 2016-05-12
KR101804479B1 (ko) 2017-12-05
MX2012003951A (es) 2012-05-29
KR20190028823A (ko) 2019-03-19
AU2010304922B2 (en) 2014-11-06
KR20230012104A (ko) 2023-01-25
IL250733A0 (en) 2017-04-30
TW201113030A (en) 2011-04-16
US20200247863A1 (en) 2020-08-06
IL218548A (en) 2017-03-30
KR20190067256A (ko) 2019-06-14
RU2724528C2 (ru) 2020-06-23
DK2486051T3 (da) 2020-06-22
CN102549011A (zh) 2012-07-04
EP2486051A1 (en) 2012-08-15
JP7292153B2 (ja) 2023-06-16
LT2486051T (lt) 2020-07-10
US20130023476A1 (en) 2013-01-24
RU2588650C2 (ru) 2016-07-10
TWI532495B (zh) 2016-05-11
WO2011042688A1 (en) 2011-04-14
PL2486051T3 (pl) 2020-09-07
AR079876A1 (es) 2012-02-29
US20140249082A1 (en) 2014-09-04
IL250733B (en) 2019-07-31
KR20210141771A (ko) 2021-11-23
RU2012112907A (ru) 2013-11-10
JP6310440B2 (ja) 2018-04-11
US10526390B2 (en) 2020-01-07
JOP20200039A1 (ar) 2022-10-30
KR20210014767A (ko) 2021-02-09
JP2021176867A (ja) 2021-11-11
ES2798258T3 (es) 2020-12-10
US11292824B2 (en) 2022-04-05
CA2776790A1 (en) 2011-04-14
KR101987982B1 (ko) 2019-06-11
JP2023075144A (ja) 2023-05-30
KR20170133531A (ko) 2017-12-05
RS60413B1 (sr) 2020-07-31
KR102213154B1 (ko) 2021-02-05
JP6176924B2 (ja) 2017-08-09
JP7196244B2 (ja) 2022-12-26
JP2013506708A (ja) 2013-02-28
JP6580104B2 (ja) 2019-09-25
IN2012DN02073A (es) 2015-08-21
EP2486051B1 (en) 2020-03-25
CN107050434A (zh) 2017-08-18
HRP20200941T1 (hr) 2020-09-18
HUE050793T2 (hu) 2021-01-28
CN107050434B (zh) 2021-07-27
RU2016118236A3 (es) 2019-09-18
BR112012007990A2 (pt) 2017-07-25
IL267556A (en) 2019-08-29
US9676835B2 (en) 2017-06-13
IL218548A0 (en) 2012-05-31
TW201632198A (zh) 2016-09-16
PT2486051T (pt) 2020-06-17
KR102489143B1 (ko) 2023-01-13
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11

Similar Documents

Publication Publication Date Title
AR125991A2 (es) Preparación farmacéutica
NZ596849A (en) Serum amyloid p derivatives and their preparation and use
PE20091352A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
RS54905B1 (sr) Poboljšani rekombinantni humani folikulo-stimulišući hormon
WO2011124953A3 (en) Controlled release pharmaceutical compositions of tapentadol
PH12013502192A1 (en) Antibodies against human angiopoietin 2
UY33391A (es) Formulaciones de insulina de acción prolongada
MX2010008138A (es) Forma de dosis farmaceutica.
CO6382140A2 (es) Composiciones de vacuna que comprenden una proteina de enlace del factor h mutada
MY192113A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
EP2073840A4 (en) MODIFIED GP140 ENVELOPE POLYPEPTIDES FROM HIV-1 ISOLATES, COMPOSITIONS, TRIMERIC COMPLEXES AND USES THEREOF
ECSP088949A (es) Polipéptidos de factor de crecimiento de tipo insulina estabilizada
AR067887A1 (es) Composicion medica con contenido de rebamipide
WO2009049284A3 (en) Compositions and methods for improved glycoprotein sialylation
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
NZ600891A (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
BR112015024609A2 (pt) proteína tendo atividade de xilose isomerase e utilização da mesma
BRPI0917656A2 (pt) Fatores viii e ix humanos produzidos de forma recombinante
PE20180324A1 (es) 1h-pirazol-5-olato sodico sustituido
TR201901259T4 (tr) Karaciğere özgü tanı için hidrofobik modifiye peptidler.
MX2010002812A (es) Composiciones alimenticias que contienen extractos de melisa.
NZ596501A (en) Casb7439 constructs
WO2007136763A3 (en) Immunological composition
EA201101638A1 (ru) Новые твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения
ECSP088574A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica